Singapore has approved a second oral antiviral drug for treating COVID-19.
Molnupiravir, branded as Lagevrio, was granted interim authorization under the Pandemic Special Access Route (PSAR) by the Health Sciences Authority (HSA) on April 19.
An experimental COVID-19 treatment pill called molnupiravir being developed by Merck & Co. Inc. and Ridgeback Biotherapeutics LP, is seen in this undated photo obtained by Reuters on May 17, 2021. Merck & Co. Inc./Handout via Reuters
|Updated:
